NVST News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NV

Mkt Cap

$3.68B

Volume

1.88M

Next Earnings

November 4th

Loading chart

NV

NVSTEnvista Holdings Corporation Common stock, $0.01 par value per share

NVST

Pay with—

Available Balance0.00

NV

Mkt Cap

$3.77B

Volume

1.88M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Envista (NVST) is a Top-Ranked Value Stock: Should You Buy?Envista (NVST), a dental platform company formed from Danaher's dental businesses, holds a #3 (Hold) Zacks Rank with a B VGM Score and A Value Style Score. The company features an attractive forward P/E ratio of 14.86 and has demonstrated a +19.4% average earnings surprise, making it a consideration for value-focused investors despite its hold rating.Zacks Investment Research · Oct 9, 2026

Here's Why Envista (NVST) is a Strong Growth StockZacks Premium offers investment research tools including Style Scores (Value, Growth, Momentum, and VGM) that complement the Zacks Rank system to help investors identify stocks with the best performance potential. The Zacks Rank has historically outperformed the S&P 500 with an average annual return of +23.86% since 1988. Envista (NVST) is highlighted as a stock to watch with a #3 Hold rank and B-rated Growth and VGM Style Scores, forecasting 28.6% year-over-year earnings growth.Zacks Investment Research · Oct 8, 2026

Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?Cooper Companies director Paul Keel purchased 4,701 shares worth $250,000 at $53.18 per share on September 11, 2026, following a 21% year-long stock decline. The insider buy is viewed as a bullish signal, suggesting confidence in the company's long-term growth prospects. Keel, who recently joined Cooper's board in May, brings extensive experience from his CEO role at Envista Holdings and prior positions at 3M.The Motley Fool · Oct 7, 2026

Best Value Stocks to Buy for September 21stZacks highlights three stocks with Rank #1 (Strong Buy) ratings and strong value characteristics: Slide Insurance Holdings (SLDE) with a P/E of 6.59 and Value Score A, Howard Hughes Holdings (HHH) with a P/E of 12.68 and Value Score A, and Envista Holdings (NVST) with a P/E of 15.25 and Value Score B. All three have seen recent increases in earnings consensus estimates.Zacks Investment Research · Sep 21, 2026

NVST or ABT: Which Is the Better Value Stock Right Now?In a comparison of two Medical Products stocks, Envista (NVST) emerges as the superior value option over Abbott (ABT). NVST holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 17.51 and PEG ratio of 1.28. ABT has a Zacks Rank #3 (Hold) with a Value grade of C, with higher valuations at P/E of 19.11 and PEG of 1.96. Based on stronger earnings outlook and more attractive valuation metrics, NVST is positioned as the better value investment.Zacks Investment Research · Sep 9, 2026

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin PressureDENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS. Wellspect Healthcare grew 7.1%, but three dental segments declined, with tariff pressures and lower volumes constraining operating margins. Free cash flow improved to $55M from $16M year-ago.Zacks Investment Research · Sep 8, 2026

Zacks.com featured highlights include Dollar General, Envista, Match and The AllstateAs the stock market hovers near record levels amid elevated Treasury yields and inflation concerns, Zacks highlights four fundamentally sound companies trading at reasonable valuations using PEG ratio analysis. The featured stocks—Dollar General, Envista, Match Group, and Allstate—offer attractive value opportunities for investors seeking alternatives to high-momentum technology and AI stocks.Zacks Investment Research · Aug 31, 2026

Global Dental Imaging Equipment Market to Reach USD 4.74 Billion by 2031, Driven by Technological AdvancementsThe global dental imaging equipment market is projected to expand from USD 3.36 billion in 2026 to USD 4.74 billion by 2031, growing at a 7.1% CAGR. Growth is driven by increased demand for digital and 3D imaging technologies, rising dental disorders, and expanding dental infrastructure, though high capital costs and regulatory challenges remain constraints.GlobeNewswire Inc. · Jul 3, 2026

$13+ Bn Dental Laboratories Market - Global Forecast to 2030 Featuring Dentsply Sirona, Envista, Ivoclar Vivadent AG, and Planmeca OyThe global dental laboratories market is projected to grow from USD 9.20 billion in 2025 to USD 13.09 billion by 2030, with a CAGR of 7.3%. Growth is driven by rising dental disorders, aging populations, and technological advancements including digital workflows, CAD/CAM systems, and 3D printing. North America leads the market, with CAD/CAM materials dominating the product segment.GlobeNewswire Inc. · Apr 13, 2026

Global Shift to Clear Aligners to Build a USD 99.44 Billion Market by 2034The global clear aligners market is valued at $11.23 billion in 2026 and is expected to grow to $99.44 billion by 2034, expanding at a 31.34% CAGR. North America leads the market while Asia Pacific shows the fastest growth. Adults dominate by age segment, polyurethane leads by material type, and online distribution channels are expected to grow fastest. Key drivers include rising demand for aesthetic orthodontic solutions, technological advancements in 3D imaging and AI, and expanding access through digital platforms.GlobeNewswire Inc. · Feb 10, 2026

to start trading

NV

NVSTEnvista Holdings Corporation Common stock, $0.01 par value per share

NVST

Pay with—

Available Balance0.00

Your PositionYou don't own any NVST yet.

Related Tickers

Earnings